Understanding the Market | JW THERAP-B rose over 10% as reports suggest its CAR-T drug is expected to enter the commercial insurance catalog
JW THERAP-B rose over 10%, as of the time of writing, it increased by 9.77%, priced at HKD 3.82, with a transaction volume of HKD 4.6331 million. According to a report by Yicai, on November 2, it was learned that JW THERAP's CAR-T cell drug, Rukiyolunase injection, is making smooth progress in negotiations to enter the commercial health insurance innovative drug catalog, with hopes of being included in the catalog, reducing the medication burden for patients and benefiting more patients. This is the first domestically approved Class 1 CAR-T in China, with a post-listing price of 1.29 million yuan per injection. On October 30, JW THERAP announced the signing of a strategic cooperation supplementary agreement with Regeneron Pharmaceuticals. This revision not only marks an important upgrade in the long-term cooperative relationship between the two parties but also opens a new phase of collaboration in TCR-T cell therapy and platform technology innovation. Through this supplementary agreement, JW THERAP will receive payments of up to USD 50 million, including milestone payments for MAGE-A4 product development, drug production process supervision milestone payments, option exercise fees, and milestone payments for lentiviral vector manufacturing processes
According to Zhitong Finance APP, JW THERAP-B (02126) rose over 10%, and as of the time of writing, it is up 9.77%, priced at HKD 3.82, with a transaction volume of HKD 4.6331 million.
In terms of news, according to Yicai, on November 2, it was reported that JW THERAP's CAR-T cell drug, Rukiyolun Injection, is making smooth progress in negotiations to be included in the commercial health insurance innovative drug directory, which is expected to reduce the medication burden on patients and benefit more patients. This is the first domestically approved Class 1 CAR-T in China, with a post-listing price of 1.29 million yuan per injection.
On October 30, JW THERAP announced the signing of a supplementary strategic cooperation agreement with Regeneron Pharmaceuticals. This revision not only marks an important upgrade in the long-term cooperative relationship between the two parties but also opens a new phase of collaboration in TCR-T cell therapy and platform technology innovation. Through this supplementary agreement, JW THERAP will receive payments of up to USD 50 million, including milestone payments for MAGE-A4 product development, drug production process supervision, option exercise fees, and milestone payments for lentiviral vector manufacturing processes
